DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS In an interim look at the SKYSCRAPER-01 study, investigators found tiragolumab plus atezolizumab didn’t meaningfully slow tumor progression compared to atezolizumab alone in patients with advanced, newly diagnosed non-small cell lung cancer (NSCLC). Tiragolumab has now fallen short in two phase 3 lung cancer trials, having already missed its study objectives in advanced SCLC earlier this year.
Peer-influenced content. Sources you trust. No registration required. This is HCN.